摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

diethyl 3-aminopent-2-enedioate | 54889-50-8

中文名称
——
中文别名
——
英文名称
diethyl 3-aminopent-2-enedioate
英文别名
diethyl 3-aminoglutaconate;2-Pentenedioic acid, 3-amino-, diethyl ester;diethyl (Z)-3-aminopent-2-enedioate
diethyl 3-aminopent-2-enedioate化学式
CAS
54889-50-8
化学式
C9H15NO4
mdl
——
分子量
201.222
InChiKey
OKSCSBYHIMCKQY-ALCCZGGFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    14
  • 可旋转键数:
    7
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    78.6
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    diethyl 3-aminopent-2-enedioate 在 ammonium cerium(IV) nitrate 作用下, 以 乙醇溶剂黄146丙酮 为溶剂, 反应 0.42h, 生成 diethyl (3,5-diethoxycarbonyl-4-phenylpyridine-2,6-diyl)-2,6-diacetate
    参考文献:
    名称:
    β-Enaminoesters as building blocks in heterocyclic synthesis. A novel synthesis of fused azines by using blaise reaction as a key step
    摘要:
    DOI:
    10.1002/(sici)1521-3897(199902)341:2<147::aid-prac147>3.0.co;2-i
  • 作为产物:
    参考文献:
    名称:
    β-Enaminoesters as building blocks in heterocyclic synthesis. A novel synthesis of fused azines by using blaise reaction as a key step
    摘要:
    DOI:
    10.1002/(sici)1521-3897(199902)341:2<147::aid-prac147>3.0.co;2-i
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
    申请人:GLAXOSMITHKLINE LLC
    公开号:US20150152108A1
    公开(公告)日:2015-06-04
    The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    本发明涉及新型取代桥式脲化合物,相应的相关类似物,药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命,并治疗和/或预防各种疾病和疾病,包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病,以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
  • Substituted 1,4-dihydropyridine compounds as bradykinin antagonists
    申请人:——
    公开号:US20020042421A1
    公开(公告)日:2002-04-11
    This invention provides a compound of the formula (I): 1 or the pharmaceutically acceptable salts thereof wherein A is independently halo; Y is —(CH 2 ) m— , —C(O)— or —S(O)—; R 1 and R 2 are independently C 1-4 alkyl; R 3 is C 7-9 bicycloalkyl, C 5-7 azacycloalkyl or C 7-9 azabicycloalkyl, the C 7-9 bicycloalkyl, C 5-7 azacycloalkyl or C 7-9 azabicycloalkyl being optionally substituted with one, two or three substituents are independently selected from oxo, hydroxyl, C 1-4 alkyl, C 1-4 alkyloxy, C 1-4 alkyl-carbonyl, formyl, C 1-4 alkylenedioxy, and phenyl-C 1-4 alkyl; R 4 is thiazolyl, imidazolyl or oxazolyl, the thiazolyl, imidazolyl or oxazolyl being optionally substituted with one or two substituents independently selected from C 1-4 alkyl and halo; R 5 is hydrogen or C 1-4 alkyl;m is 0, 1 or 2; and n is 0, 1, 2, 3, 4 or 5. These compounds are usefuil for the treatment of medical conditions mediated by bradykinin such as inflammation, allergic rhinitis, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.
    这项发明提供了以下式(I)的化合物或其药学上可接受的盐,其中A独立表示卤素;Y为—(CH2)m—,—C(O)—或—S(O)—;R1和R2独立表示C1-4烷基;R3为C7-9双环烷基,C5-7杂环烷基或C7-9杂双环烷基,其中C7-9双环烷基,C5-7杂环烷基或C7-9杂双环烷基可以选择性地被一个、两个或三个取代基取代,这些取代基独立地选自氧代、羟基、C1-4烷基、C1-4烷氧基、C1-4烷基羰基、甲酰基、C1-4烷基二氧基和苯基-C1-4烷基;R4为噻唑基、咪唑基或氧唑基,其中噻唑基、咪唑基或氧唑基可以选择性地被一个或两个取代基独立地选自C1-4烷基和卤素取代;R5为氢或C1-4烷基;m为0、1或2;n为0、1、2、3、4或5。这些化合物可用于治疗由激肽酶介导的医疗状况,如炎症、过敏性鼻炎、疼痛等。这项发明还提供了包含上述化合物的药物组合物。
  • Substituted bridged urea analogs as sirtuin modulators
    申请人:GLAXOSMITHKLINE LLC
    公开号:US10590135B2
    公开(公告)日:2020-03-17
    The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    本发明涉及新型取代桥基脲化合物、相应的相关类似物、药物组合物及其使用方法。本发明的Sirtuin调节化合物可用于增加细胞的寿命,治疗和/或预防多种疾病和失调,这些疾病和失调包括但不限于例如与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、凝血障碍、炎症、癌症和/或潮红有关的疾病或失调,以及将受益于线粒体活性增加的疾病或失调。本发明还涉及由sirtuin调节化合物与另一种治疗剂组合而成的组合物。
  • Reaction of 3-amino-2-benzoylcrotonate esters with phosgene
    作者:Frederick E. Ward、Robert T. Buckler
    DOI:10.1021/jo01311a012
    日期:1980.11
  • WARD F. E.; BUCKLER R. T., J. ORG. CHEM., 1980, 45, NO 23, 4608-4611
    作者:WARD F. E.、 BUCKLER R. T.
    DOI:——
    日期:——
查看更多